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Summary. FOXP1 protein is expressed in normal
activated B cells and overexpressed in a subset of diffuse
large B-cell lymphomas, including primary cutaneous
large B-cell lymphomas (PCLBCL), leg type. High
expression of FOXP1 has been associated to an
unfavourable prognosis with independent survival
significance. However, little is known regarding the
mechanisms underlying the overexpression of FOXP1 in
PCLBCL, leg type. Our aims were to analyze FOXP1
cytogenetic status and protein expression in a series of
PCLBCL, leg type. Finally, we compared the observed
results with those obtained in a group of patients with
primary cutaneous follicle centre lymphoma (PCFCL).
Fifteen patients with PCLBCL, leg type and nine
patients with primary cutaneous follicle centre
lymphoma (PCFCL) were included in the study. For
each biopsy specimen, FOXP1 translocation and copy
number changes were evaluated by fluorescence in situ
hybridization (FISH) and protein expression by
immunohistochemistry (IHC).
Immunohistochemistry showed FOXP1 staining in
13 PCLBCL, leg type, whereas all PCFCL were
negative. FISH analysis disclosed no translocations
involving FOXP1 gene in any of the cases. However,
FOXP1 gene gains (3 to 4 copies) were observed in 82%
of samples of PCLBCL, leg type and in 37% of PCFCL.
FOXP1 expression was independent from FOXP1
translocation. 
Our results confirm that overexpression of FOXP1 is
present in a considerable proportion of PCLBCL, leg
type and might indicate an unfavourable prognosis.
Mechanisms not related to translocation seem to be
responsible for this overexpression. 
Key wods: Cutaneous lymphoma, Leg type, Large B
cell, FOXP1, FISH
Introduction
Primary cutaneous diffuse large B-cell lymphoma,
leg type (PCLBCL, leg type) is a subgroup of primary
cutaneous B-cell lymphomas, characterized clinically by
red or violaceous plaques or nodules, often (but not
exclusively) arising on one or both legs, and
histologically by a neoplastic proliferation comprised of
confluent sheets of centroblasts and immunoblasts
(Willemze et al., 2005). The new WHO classification of
tumors of hematopoietic and lymphoid tissues
recognizes PCLBCL, leg type as a separate entity with
an intermediate prognosis, frequent dissemination to
extracutaneous sites and a short survival (Swerdlow et
al., 2008). 
Primary cutaneous follicle centre lymphoma
(PCFCL) is another type of cutaneous B cell lymphoma
with the presence of large neoplastic cells, particulary
large centrocytes. PCFCL usually presents with skin
lesions confined to a limited skin area on the head and
trunk, rarely disseminates to extracutaneous localizations
and usually has an excellent outcome (Senff et al.,
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2007). 
Recent studies have evaluated the genetic and gene
expression profile, suggesting that PCFCL and
PCLBCL, leg type show profiles similar to that of
germinal center B-cell (GBC)-like and activated B-cell
(ABC)-like diffuse large B-cell lymphomas (DLBCL),
respectively (Hoefnagel et al., 2005).
Forkhead box-P1 (FOXP1) gene codifies for a
transcription factor involved in the transcriptional
regulatory network of B lymphopoiesis (Hu et al., 2006;
Dengler et al., 2008), expressed in normal activated B
cells (Shaffer et al., 2002) and overexpressed in a subset
of systemic DLBCL with a predominantly ABC-like
phenotype (Barrans et al., 2004; Banham et al., 2005).
Among primary cutaneous lymphomas, FOXP1 protein
expression has been detected in more than 70% of cases
of PCLBCL, leg type, but it is observed in less than 10%
of PCFCL (Kodama et al., 2005; Hoefnagel et al., 2006).
A possible relationship between FOXP1 expression and
the clinical and evolutive features has been described
(Hallermann et al., 2007), and suggesting a role for
FOXP1 in the pathogenesis of PCLBCL, leg type.
Recurrent chromosomal translocations targeting the
FOXP1, which commonly but not exclusively involve
the IGH locus leading to the translocation
t(3;14)(p14;q32), have been described in systemic
DLBCL and marginal zone lymphomas of mucosa-
associated lymphoid tissue (MALT) (Streubel et al.,
2005; Wlodarska et al., 2005; Fenton et al., 2006; Goatly
et al., 2008). However, the mechanisms by which
FOXP1 expression is deregulated in PCLBCL, leg type
are largely unknown.
The aims of the present study were to analyze
FOXP1 cytogenetic status and protein expression in a
series of PCLBCL, leg type. We designed a dual color,
break-apart probes to study the genetic abnormalities of
this locus, and correlations between FOXP1 protein
expression and FOXP1 gene status were also
investigated. Finally, we compared the observed results
with those obtained in a group of patients with primary
cutaneous follicle centre lymphoma (PCFCL).
Materials and methods
Patient selection
Fifteen patients diagnosed with PCLBCL, leg type
were retrieved retrospectively from the Catalonian
Cutaneous Lymphoma Network database (Hospital de
Bellvitge, Hospital del Mar and Hospital Clinic,
Barcelona) and were included in the study. The
diagnosis of primary cutaneous involvement was
established on the basis of an exclusive skin involvement
at diagnosis, and following a complete staging work-up.
In addition, a group of nine patients diagnosed with
PCFCL showing a prominent large cell population were
included in the study. All cases fulfilled the standard
classification criteria of the last World Health
Organization (WHO) classification (Swerdlow et al.,
2008).
Clinical features
For each patient, the following clinical data were
collected: age, sex, time period prior to diagnosis,
primary anatomic site, number of lesions or disease
extension, staging, type of treatment, response to
treatment, evolution including cutaneous recurrence,
time to first relapse, development of extracutaneous
disease, current status and follow-up duration. 
Histologic examination and immunohistochemistry
Formalin-fixed paraffin embedded tissues were
retrieved from each case. Immunohistochemical studies
for FOXP1 were performed in 4 µm tissue sections
previously deparaffinized and rehydrated. Sections were
heat-retrieved for antigen in a high pH Dako solution
(pH 9.9) using a microwave pressure cooker system.
Immunohistochemistry was performed with an
automated immunostainer (Dako TechMate Immuno-
stainer, Dako, Glostrup, Denmark) using a monoclonal
anti-FOXP1 antibody (clone JC12, dilution 1:50) kindly
provided by Dr. Alison H. Banham (Nuffield
Department of Expression Clinical and Laboratory
Sciences, University of Oxford, UK). FOXP1 expression
by tumor cells was assessed at four levels of intensity
(0=negative, 1=weak, 2=moderate, 3=strong) and four
groups defining the percentage of positive cells (<25%
negative, 25-50%, 50-75% and >75%). The rest of the
antibodies used for the phenotypic characterization of
these lesions were performed as previously described
(Colomo et al., 2003). 
Fluorescence in situ hybridization (FISH)
FISH analyses were performed in all samples on
paraffin sections following standard procedures. A
FOXP1 (3p14.1) dual color break-apart non-commercial
probe was designed using two bacterial artificial
chromosomes (BACs) from the Children’s Oakland
Research Institute library: RP11-79P21 located at 3’ of
the gene labelled with SpectrumRed (Abbot Molecular,
Abbott Park, IL) and RP11-713J7 located at 5’ of the
gene and labelled with SpectrumGreen (Abbot
Molecular) (Fig. 1a) (Baró et al., 2009). FISH was
analyzed in parallel sections from those studied for
immunohistochemistry and morphology. Slides were
evaluated in a fluorescence microscope (BX51,
Olympus, Spain). The expected pattern in a nucleus
harboring a FOXP1 translocation was one fused red-
green signal (1F), representing the normal chromosome
3, one red signal (1R) and one green signal (1G)
representing the translocated chromosome 3 (1F1R1G
pattern). A normal case should show two fused red-
green signals (2F) and a case with trisomy or tetrasomy
of FOXP1 gene should show three or four fused red-
green signals (3F or 4F) (Figure 1b). Moreover, in 3
cases (one PCFCL and two PCLBCL, leg type cases)
FISH using the centromeric probe for chromosome 3
labelled in orange (CEP3, Abbot Molecular) and the
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BAC RP11-713J7 located at 5’of the gene labelled in
green was performed to test the presence of trisomy. 
To assess the cut-off values of the tested FISH
probes in healthy individuals, five paraffin-embedded
tonsil tissue sections and ten peripheral blood samples
from healthy donors were used as negative controls. The
cut-off values were calculated as the mean of false-
positive findings plus three times the standard deviation.
Two hundred nuclei per case were scored by two
different observers, taking into account the following
abnormal patterns: 1F1R1G, 1F, 3F. The calculated
values for these patterns in control tissues were 2%, 54%
and 10%, respectively. In addition, three samples from
patients affected with a DLBCL harbouring a FOXP1
translocation previously detected by G-banding
cytogenetics and/or FISH were included in the study as
positive controls (kindly provided by Dr. Berthold
Streubel from Department of Pathology, Medical
University of Vienna, Vienna, Austia, and Dr. Iwona
Wlodarska from Department of Haematology, University
Hospital Gasthuisberg, Leuven, Belgium).
Finally, kappa/cross test was performed to assess the
agreement between FOXP1 expression and FISH results.
Results
Clinical data
Patients with PCLBCL, leg type were seven men
and eight women with a mean age of 68 years. The
lesions corresponded to solitary nodules/tumors located
on the leg (n=10) (Fig. 2a) and the trunk (n=2), or
disseminated lesions (n=3). Patients with PCFCL were
six men and three women (mean age 58 years). The
lesions were present on the trunk (n=5) (Fig. 2c) or face
(n=4). The clinical data are summarized in Table 1.
Patients with PCLBCL, leg type presenting early
cutaneous stage of the disease were treated with
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Fig. 1. A. Diagram of the FOXP1 (3p14.1) dual color break-apart probe design, using two bacterial artificial chromosomes (BACs) from the Children’s
Oakland Research Institute library: RP11-79P21 located at 3’ of the gene labelled with SpectrumRed (Abbott Molecular) and RP11-713J7 located at 5’
of the gene and labelled with SpectrumGreen (Abbott Molecular). B. Schematic representation of different FISH patterns found in the present study
using the FOXP1 dual color break-apart non-commercial probe in interphase nuclei. The circles represent different nuclei and inside them there are
different combinations of red and green dots representing 5’FOXP1 and 3’FOXP1 probe signals. Below each nucleus the nomenclature of the FISH
patterns is indicated. Abbreviations: R: red; G: green; F: fusion
localized skin radiation therapy (RT) (n=8). For those
patients with more advanced skin disease, chemotherapy
alone (n=4) or in combination with RT (n=2) was
prescribed. In one patient, no treatment was
administered due to the poor performance status of the
patient. After the initial treatment, 11 out of 14 patients
achieved a complete response (78%). Seven patients
experienced one or several relapses (cutaneous or
extracutaneous). In total, nine out of 15 PCLBCL, leg
type cases developed extracutaneous disease (lymph
nodes [n=6], testis [n=2], central nervous system [n=1])
after a follow-up period ranging from 4-96 months
(mean, 31 months). Six out of 15 patients died of
lymphoma progression, five patients were alive (two of
them presenting skin residual disease) and four died of
unrelated causes.
In contrast, in all PCFCL cases a complete remission
was obtained after an initial therapeutic approach (RT
[n=6], surgery [n=2] or chemotherapy [n=1]). Two
PCFCL presented limited skin relapses after the first
treatment. The mean follow-up period for this group of
patients was 55 months (range, 12-121 months). Clinical
status at the end of the study was as follows: eight out of
nine patients with PCFCL were in complete remission.
and one patient died of an unrelated cause within this
group. 
Histopathological and immunohistochemical data
Histopathological and immunohistochemical
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Fig. 2. Clinical presentation and histology pattern of PCLBCL. A. Clinical presentation of a primary cutaneous large B-cell lymphoma, leg type with a
tumor on the left lower leg. B. Typical presentation of primary cutaneous follicle center lymphoma on the chest surrounded by less infiltrated
erythematous skin areas. C. Diffuse infiltrate of centroblasts and immunoblasts. Hematoxilin-Eosin staining. x100. D. Diffuse dermal infiltrate with large
centrocytes and multibobated cells. Hematoxilin-Eosin staining. x100
features of all included cases are described in Table 2. A
diffuse, monomorphic dermal or subcutaneous
infiltration by a proliferation of large B cells,
predominantly centroblasts and immunoblasts with
scattered centrocytes, was observed in PCLBCL, leg
type cases (Fig. 2b). Thirteen (87%) PCLBCL, leg type
cases were positive for the FOXP1 antigen. Among
them, one case was weak, seven cases had moderate
expression, and five showed strong FOXP1 positivity
(Fig. 3). 
Expression of BCL2 in more than 50% of the
neoplastic cells was observed in all the cases of
PCLBCL, leg type cases, whereas a positive staining for
MUM1 protein was present in 10 of 14 available tumors.
Bcl-6 was expressed in six of 14 (43%) tumors and
CD10 was weakly expressed in two out of 15 (13%)
cases. 
Neoplastic cells of PCFCL corresponded to large
cleaved cells and showed a rather polymorphous
appearance (Fig. 2d). Immunohistochemistry for FOXP1
was successfully performed in six out of nine cases and
all evaluated samples were negative for FOXP1
expression (Fig. 3). Three cases expressed BCL2 but
with less intensity than admixed T cells. MUM1 was
negative in all nine cases examined and expression of
CD10 was identified in four (44%) cases and Bcl6 was
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Table 1. Clinical characteristics of a series of 24 PCLCL.
CBCL subtype AgeSex Site Clinical features Initial therapy First recurrence Nº of Extracutaneous Follow-up Status
and Response (months) recurrences involvement (months)
(months )
PCLBCL, leg-1 64 F LEG grouped tumors PD after CHOP skin (same site) progression LN (8) 23 Death of disease
PCLBCL, leg-2 77 M LEG grouped tumors CR after CHOP+ RDT testis NO TESTIS (6) 17 Death of unrelated
causes
PCLBCL, leg-3 69 M TRUNK grouped tumors CR after local RDT NO NO NO 13 Alive with no disease
PCLBCL, leg-4 81 F LEG grouped tumors CR after local RDT skin, local 1 LN (9) 19 Death of disease
lymph nodes
PCLBCL, leg-5 83 F LEG solitary nodule none NO NA NA 4 Death of unrelated
causes
PCLBCL, leg-6 64 F LEG multiple infiltrated CR after local RDT UK UK NO 12 Alive with no disease
plaques and nodules
PCLBCL, leg-7 80 F DISSEMINATED multiple infiltrated CR after RDT NO NO NO 14 Alive with no disease
plaques and nodules
PCLBCL, leg-8 61 F LEG multiple infiltrated CR after local RDT skin (24) progression LN (24) 72 Death of disease
plaques and nodules
PCLBCL, leg-9 88 F DISSEMINATED multiple infiltrated PR after cyclofosphamide progressive disease, progression LN (6) 7 Death of disease
plaques and nodules and prednisone+RDT lymph nodes
PCLBCL, leg-10 49 M DISSEMINATED multiple infiltrated CR after CHOP skin (48) progression LN (48) 96 Death of lung 
plaques and nodules adenocarcinoma
PCLBCL, leg-11 65 M LEG multiple infiltrated PD after CHOP progressive progression TESTIS (6) 32 Death of disease
plaques and nodules disease, testis
PCLBCL, leg-12 86 M TRUNK solitary nodule CR after local RDT lymph nodes 1 LN (6) 26 Death of disease
PCLBCL, leg-13 76 M LEG grouped tumors CR after local RDT skin (12) 2 NO 51 Alive with no disease
PCLBCL, leg-14 89 F LEG solitary nodule CR after local RDT NO NO NO 40 Death of unrelated
causes
PCLBCL, leg-15 67 M LEG grouped tumors CR after R-EPOCH skin (15), progressive 2 CNS (40) 44 Alive with disease
disease CNS
PCFCL-1 60 M TRUNK multiple nodules CR after local RDT NO NO NO 14 Alive with no disease
PCFCL-2 37 F TRUNK multiple infiltrated CR after local RDT NO NO NO 12 Alive with no disease
plaques and nodules
PCFCL-3 51 M TRUNK multiple infiltrated CR after local RDT skin (40) 4 NO 121 Alive with disease
plaques and nodules
PCFCL-4 82 M HEAD AND NECK grouped tumors CR after local RDT skin (10) 3 NO 61 Death of unrelated
causes
PCFCL-5 75 M TRUNK multiple infiltrated CR after local RDT NO NO NO 43 Alive with no disease
plaques and nodules
PCFCL-6 71 F HEAD AND NECK solitary nodule CR after surgery NO NO NO 28 Alive with no disease
PCFCL-7 37 F HEAD AND NECK solitary nodule CR after surgery NO NO NO 34 Alive with no disease
PCFCL-8 65 M HEAD AND NECK grouped tumors CR after CHOP NO NO NO 36 Alive with no disease
PCFCL-9 46 M TRUNK grouped tumors CR after local RDT NO NO NO 96 Alive with no disease
PCFCL: primary cutaneous follicle center lymphoma; PCLBCL, leg type: primary cutaneous large B-cell lymphoma, leg type; M: male; F: female; PD:
progressive disease; PR: partial remission; CR: complete remission; RDT: radiotherapy; CHOP: Ciclophosphamide, Doxorubicin, Vincristine and
Prednisolone; R-EPOCH: Rituximab, Etoposide, Ciclophosphamide, Doxorubicin, Vincristine and Prednisolone; NA: not available; UK: unknown.
positive in all PCFCL studied.
FISH results
Eleven cases of PCLBCL, leg type were examined
for translocations using FISH analysis with the FOXP1
(3p14.1) dual color break-apart non-commercial probe.
As summarized in Table 2, none of the analyzed cases
displayed translocations involving the FOXP1 gene.
Two cases of PCLBCL, leg type presented a normal
FISH pattern and nine cases showed a 3F/4F pattern
(Fig. 3). Two cases with extra copies for FOXP1 gene
that had sufficient material for additional FISH analysis
had displayed extra copies of the chromosome 3. All
cases with gains of FOXP1 gene except one, presented
overexpression of the FOXP1 protein in more than 50%
of tumoral cells. However, FOXP1 was also expressed in
two cases without extra copies for FOXP1.
Available FISH results were obtained in 8 out of 9
cases of PCFCL. No translocations of the FOXP1 gene
were detected. Among PCFCL, five cases showed a
normal 2F pattern (Fig. 3) and three cases displayed
extra copies of FOXP1 gene (3 to 4 copies) with a 3F/4F
pattern, in absence of protein expression. Poliploidy of
chromosome 3 using the CEP3 probe was detected in
one patient with extra copies for FOXP1 gene. However,
no statistical relationship could be assessed between
FOXP1 expression and FOXP1 gene status. 
Discussion
PCLBCL, leg type is an aggressive tumor that may
occur in locations other than the leg, and overlapping
clinical and morphological features with PCFCL may
exist, particularly in cases of PCFCL mainly composed
by large cells. FOXP1 protein expression has been
postulated as a useful tool to distinguish both entities.
However, there is no information regarding FOXP1 gene
alterations in primary cutaneous lymphomas. The
current study was designed to investigate FOXP1 gene
status (numerical and structural aberrations) in a series
of PCLBCL, leg type and PCFCL patients using paraffin
section interphase FISH analysis. A screening approach
using a dual color break-apart probe for FOXP1 locus
was used because this technique allows the identification
of rearrangements at the FOXP1 gene region, regardless
of what other chromosomal regions are involved.
In our series, we observed a high expression of
FOXP1 protein (87%) in PCLBCL, leg type. In contrast,
PCFCL were all negative for FOXP1 in the six cases
with available material. Similar results have been
reported in the literature. Kodama et al. (2005),
Hoefnagel et al. (2006) and more recently Hallermann et
al. (2007) reported that 23/29, 11/11 and 19/21 of
PCLBCL, leg type expressed FOXP1, respectively.
FISH studies have not shown the presence of
rearrangements involving the FOXP1 gene among our
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Table 2. Histological, immunophenotypical and molecular cytogenetics characteristics of a series of 24 PCLCL.
CBCL subtype Morphology, pattern Predominant cell morphology BCL2 MUM1 BCL6 CD10 IHC % FOXP1 FOXP1 FISH FOXP1
FOXP1 positive cells intensity
PCLBCL, leg-1 Diffuse, dermis Centroblasts POS POS NEG NEG NEG NEG NEG 3-4 COPIES
PCLBCL, leg-2 Diffuse, dermis + subcutis Centroblasts POS POS POS NEG POS >75 2 3-4 COPIES
PCLBCL, leg-3 Diffuse, dermis Centroblasts POS POS POS NEG POS 50-75 2 3-4 COPIES
PCLBCL, leg-4 Diffuse, dermis + subcutis Centroblasts POS POS NEG NEG POS >75 2 3-4 COPIES
PCLBCL, leg-5 Diffuse, dermis + subcutis Centroblasts POS POS NEG NEG POS 25-50 2 NORMAL
PCLBCL, leg-6 Diffuse, dermis Centroblasts POS POS POS NEG POS >75 3 3-4 COPIES
PCLBCL, leg-7 Diffuse, dermis Centroblasts POS POS NEG NEG NEG NEG NEG NA
PCLBCL, leg-8 Diffuse, dermis Centroblasts / large centrocytes POS NEG NEG POS POS >75 3 NA
PCLBCL, leg-9 Diffuse, dermis Centroblasts POS NEG NEG NEG POS >75 3 NA
PCLBCL, leg-10 Diffuse, dermis Centroblasts / large centrocytes POS NEG POS NEG POS 25-50 2 NA
PCLBCL, leg-11 Diffuse, dermis Centroblasts / immunoblasts POS POS NEG NEG POS >75 1 3-4 COPIES
PCLBCL, leg-12 Diffuse, dermis Centroblasts POS POS POS NEG POS >75 3 3-4 COPIES
PCLBCL, leg-13 Diffuse, dermis + subcutis Centroblasts / immunoblasts POS NEG POS NEG POS >75 3 3-4 COPIES
PCLBCL, leg-14 Diffuse, dermis + subcutis Immunoblasts POS NA NA NEG POS 50-75 2 NORMAL
PCLBCL, leg-15 Diffuse, dermis + subcutis Centroblasts / large centrocytes POS POS NEG POS POS >75 2 3-4 COPIES
PCFCL-1 Diffuse, dermis Large centrocytes / centroblasts NEG NEG POS NEG NA NA NA NORMAL
PCFCL-2 Diffuse, dermis Large centrocytes / centroblasts NEG NEG POS NEG NA NA NA 3-4 COPIES
PCFCL-3 Diffuse, dermis + subcutis Large centrocytes / centroblasts NEG NEG POS NEG NEG NEG NEG 3-4 COPIES
PCFCL-4 Diffuse, dermis Large centrocytes / centroblasts POS NEG POS POS NA NA NA NORMAL
PCFCL-5 Diffuse, dermis Large centrocytes / centroblasts POS NEG POS NEG NEG NEG NEG 3-4 COPIES
PCFCL-6 Diffuse, dermis + subcutis Large centrocytes / centroblasts NEG NEG POS POS NEG NEG NEG NORMAL
PCFCL-7 Nodular, dermis Large centrocytes / centroblasts POS NEG POS POS NEG NEG NEG NORMAL
PCFCL-8 Nodular, dermis + subcutis Centroblasts / large centrocytes NEG NEG POS NEG NEG NEG NEG NA
PCFCL-9 Diffuse, dermis + subcutis Centroblasts / large centrocytes NEG NEG POS POS NEG NEG NEG NORMAL
PCFCL: primary cutaneous follicle center lymphoma; PCLBCL, leg type: primary cutaneous large B-cell lymphoma, leg type; POS: positive; NEG:
negative; NA: not available.
PCLBCL, leg type or PCFCL. As all samples included
in this study consistently contained more than 50% of
tumor cells, it is highly unlikely that the lack of
rearrangements detectable by FISH was caused by
technical limitations. Although FOXP1 rearrangements
have been demonstrated at a higher frequency in
extranodal DLBCL with gastric presentation
(Haralambieva et al., 2006), our results are in
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Fig. 3. Representative images of FOXP1 immunostaining and fluorescence in situ hybridization (FISH) in PCLBCL. A, B. Primary cutaneous large B-
cell lymphoma, leg type (PCLBCL, leg type) showing FOXP1 high protein expression (A) and 3F FOXP1 dual color break-apart FISH pattern (B)
indicating the presence of an extra copy of the FOXP1 gene. C, D. Primary cutaneous follicle center lymphoma (PCFCL) showing negativity for FOXP1
protein expression (C) and 2F FOXP1 dual color break-apart FISH pattern (D) indicating the absence of translocations or gains of this gene. A, C, x
600; B, D, x 1000
accordance with results of a study by Barrans et al
involving a large series of nodal and extranodal systemic
DLBCL (Barrans et al., 2007). Recently, Goatly et al.
studied a large series of 595 lymphomas by interphase
FISH with 10 BAC clones covering the whole FOXP1
gene, in order to map FOXP1 breakpoints. In this series,
there was only one case of cutaneous DLBCL, which did
not present FOXP1 translocation (Goatly et al., 2008).
Regarding FOXP1 translocations, the break-apart probe
used in the present study includes only two BAC clones,
RP11-79P21 and RP11-713J7, located at 5’ and 3’ ends
of the gene, and allows the detection of all the possible
breakpoints described by Goatly et al. (2008). 
Extra copies of the FOXP1 gene were observed in
82% of cases of PCLBCL, leg type investigated, which
supports this alteration as a mechanism of over-
expression of the protein. Interestingly, gains of genomic
material at the FOXP1 locus have also been associated
to the ABC-like DLBCL subtype, and therefore with an
adverse prognosis (Wlodarska et al., 2005; Fenton et al.,
2006; Haralambieva et al., 2006; Barrans et al., 2007).
Other mechanisms linked to increased FOXP1
expression levels are gains of the entire chromosome 3,
suggested by the presence of additional FISH signals at
the FOXP1 locus, and confirmed by conventional GTG
banding cytogenetics and FISH with a chromosome 3
alpha-satellite pericentromeric probe (Haralambieva et
al., 2006). In this way, three cases of our series with
extra copies of chromosome 3 were observed. These
cases were previously studied by conventional
comparative genomic hybridization (CGH) in a series of
18 primary and secondary cutaneous LBCL (Giménez et
al., 2005). In five cases, a gain of the centromere of
chromosome 3 was observed, and gains on 3p and/or 3q
were found in approximately 30% of cases. However,
these findings have not been confirmed in a study using
BAC-arrayCGH (Dijkman et al., 2006).
The presence of low-level gene copy number (three
to four copies) have also been described in solid tumors,
such as low-level EGFR (7p12) copy number increase in
prostate and lung cancers. In these cases, a simultaneous
increase of centromere 7 copy number in virtually all of
these cases suggests that a gain of the entire
chromosome 7 (polysomy 7) caused most EGFR copy
number gains. The clear-cut association of such low-
level gene copy number gains with EGFR protein
expression emphasizes the strong effect of minimal
DNA copy number changes on EGFR gene expression
(Schlomm et al. 2007). In contrast, in our series, two
cases of PCLBCL, leg type had strong expression of the
protein in absence of any increase in copy number and
two cases of PCFCL had gains of FOXP1 in absence of
protein expression. 
In conclusion, our observations indicate that
Aalternative mechanisms other than genetic alterations,
B-cell activation among them, are capable of
regulatating FOXP1. These results provide give
additional information regarding genetic features in
pathogenesis of PCLBCL, leg type. 
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